TP53 and head and neck squamous cell carcinoma: Considering that many preclinical studies confirmed the sensitizing effect of CHK1/2 in p53-deficient cells, and that there is a high rate of Tp53 mutation in HNSCC, the CHK1/2 pathway is emerging as a promising potential new DDR inhibitor in this setting [59,65].